For a number of cancersubtypes it is crucial to determine if a mutation is present in genes like KRAS, EGFR, BRAF and PIK3CA. The testresults will be consequently used to predict the response to therapy. We demonstrate the workflow of this process in the Molecular Tumour Diagnostics group in the department of Pathology at the Leiden University Medical Center in the Netherlands. For more information: LUMC Pathology SLMP.nl (Dutch only) Citation: Rapid KRAS, EGFR, BRAF and PIK3CA...